Glass House Brands (GLAS) Cost of Revenue (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Cost of Revenue of $30.5 million for Q1 2026, up 18.91% quarter-over-quarter from $25.6 million in Q4 2025.
Glass House Brands (GLAS) Cost of Revenue (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Cost of Revenue for 7 consecutive years, with $30.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue changed N/A year-over-year to $30.5 million; the TTM figure through Mar 2026 stood at $110.8 million (changed N/A YoY), while the FY2025 annual figure was $105.0 million, up 1.47% from the prior year.
- Cost of Revenue improved to $30.5 million in Q1 2026 per GLAS's latest filing, from $25.6 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $30.5 million in Q1 2026 and bottomed at $11.6 million in Q1 2022.
- Historically, Cost of Revenue has averaged $22.4 million across 5 years, with a median of $23.0 million in 2022.
- Annual changes were most pronounced in 2022 — Cost of Revenue soared 60.9% — and 2025, when it gained 10.58%.
- Glass House Brands' Cost of Revenue stood at $20.7 million in 2022, then dropped by 2.0% to $20.3 million in 2023, then gained by 24.5% to $25.3 million in 2024, then advanced by 1.52% to $25.6 million in 2025, then rose by 18.91% to $30.5 million in 2026.
- Business Quant data shows GLAS's Cost of Revenue at $30.5 million in Q1 2026, $25.6 million in Q4 2025, and $26.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Glass House Brands | 840.76 Mn | 822.21 Mn | 15.77 Mn | 31.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.50 Mn |
| Mar 31, 2026 | 30.50 Mn |
| Dec 31, 2025 | 25.65 Mn |
| Dec 31, 2025 | 25.65 Mn |
| Sep 30, 2025 | 26.69 Mn |
| Sep 30, 2025 | 26.69 Mn |
| Jun 30, 2025 | 27.94 Mn |
| Jun 30, 2025 | 27.94 Mn |
| Jun 30, 2024 | 25.26 Mn |
| Jun 30, 2024 | 25.26 Mn |
| Jun 30, 2023 | 20.29 Mn |
| Jun 30, 2023 | 20.29 Mn |
| Dec 31, 2022 | 20.71 Mn |
| Dec 31, 2022 | 20.71 Mn |
| Sep 30, 2022 | 19.53 Mn |
| Sep 30, 2022 | 19.53 Mn |
| Jun 30, 2022 | 16.22 Mn |
| Jun 30, 2022 | 16.22 Mn |
| Mar 31, 2022 | 11.63 Mn |
| Mar 31, 2022 | 11.63 Mn |